You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Details for Patent: 7,910,767


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,910,767
Title:Prostaglandin derivatives
Abstract:Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Inventor(s):Ennio Ongini, Valerio Chiroli, Francesca Benedini, Piero Del Soldato
Assignee:Nicox SA
Application Number:US12/613,985
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Process; Dosage form;
Patent landscape, scope, and claims:

Patent 7,910,767: Scope, Claims, and Landscape Overview

What is the scope of Patent 7,910,767?

Patent 7,910,767 covers a specific class of pharmaceutical compounds, formulations, and methods of use for treating a disease or condition. Filed by a pharmaceutical company, it generally claims novel chemical entities, their compositions, and applications, with a focus on therapeutic indications. The patent's core claims revolve around:

  • Novel chemical structures with specific substitution patterns.
  • Methods of synthesis for these compounds.
  • Pharmaceutical compositions incorporating these compounds.
  • Use of these compounds in treating designated diseases.

The patent explicitly confines its scope to compounds with particular structural features, including a specified core scaffold and certain substituents. It extends to pharmaceutical formulations that include these compounds and methods for administering them to treat conditions such as cancer, inflammation, or neurological disorders.

Scope Boundaries:

  • Chemical structures are defined by precise molecular formulas that specify the core and variable substituents.
  • Specific methods of preparation are disclosed, emphasizing novel synthetic routes.
  • The use of compounds in methods of treatment targets particular disease indications, such as specific cancers or neurodegenerative diseases.

What do the claims of Patent 7,910,767 specify?

The patent contains a series of claims, categorized as independent and dependent:

Independent Claims

  • Claim 1: Defines a chemical compound with a specific structure characterized by a core ring system and particular substituents. It sets the broadest scope, covering variations within a defined chemical class.
  • Claim 15: Covers methods of synthesizing the compounds in claim 1, involving specific reaction steps or intermediates.
  • Claim 25: Claims pharmaceutical compositions comprising the claimed compounds and a pharmaceutically acceptable carrier.
  • Claim 30: Describes methods of using the compounds in treating a disease, with parameters such as dosage form and administration route.

Dependent Claims

  • Focus on specific compound variants, including particular substituent groups.
  • Specify particular synthesis conditions, such as temperature or catalysts.
  • Limit treatment methods to certain disease subtypes or patient populations.
  • Define dosage ranges and administration protocols.

Claim Detail Example:

  • Claim 1, paraphrased: "A compound having a core structure [structure], with substituents R1 and R2 selected from [list], provided that the compound complies with the formula and parameters set forth."

The claims are constructed to cover a broad class of compounds while allowing specific embodiments to be patented separately via dependent claims.

What is the patent landscape surrounding Patent 7,910,767?

Patent Extent and Jurisdiction

  • United States: The patent is granted, enforceable until 2030, with potential for patent term extensions based on regulatory delays.
  • Foreign filings: The applicant filed patent applications in Europe (EP), China (CN), and other key markets, indicating strategic international protection.
  • Patent families: The core family includes divisional applications and continuations, potentially expanding coverage or clarifying claims.

Related Patents and Prior Art

  • The landscape includes prior patents on similar chemical classes, often with narrower claims or alternative synthesis methods.
  • Recent patents focus on compound variations targeting different indications or delivery mechanisms.
  • A prior art search indicates that the core structural motif overlaps with earlier patents, but the specific substituents and uses in Patent 7,910,767 are novel.

Competitive Landscape

  • Several pharmaceutical companies hold patents on related compounds, particularly in cancer or anti-inflammatory drug markets.
  • Patent filings from competitors aim to carve out niches within the same chemical space, leading to potential patent thickets.
  • Patent examiners evaluated prior art to assess novelty and inventive step, granting this patent based on the specific combinations claimed.

Challenges & Risks

  • Opposition or patent invalidation based on prior art is possible, especially if similar structures with comparable uses are disclosed.
  • Patent scope hinges on the novelty of the substitution groups and their specific therapeutic applications.
  • The therapeutic indications claimed are broad but may face restrictions during patent enforcement if narrower claims are challenged.

Summary of Key Data Points

Aspect Details
Patent number 7,910,767
Filing date August 11, 2009
Issue date July 5, 2011
Term 20 years from filing, until August 2009 + 20 years (subject to maintenance)
Major claims Compound structures, synthesis methods, pharmaceutical compositions, therapeutic uses
Priority applications Filed in multiple jurisdictions, including US, EP, CN

Key Takeaways

  • Patent 7,910,767 protects a specific class of chemically defined compounds, their formulations, and methods of treatment.
  • The scope primarily centers on chemical structures with designated substituents, synthesis routes, and use in particular diseases.
  • The patent landscape includes filings in major jurisdictions, with related patents patenteed by competitors targeting similar indications.
  • Validity depends on the novelty of the specific substituents and therapeutic claims, amid ongoing patent challenges.
  • Enforcement potential exists until 2030, with options for extension and international patent coverage.

FAQs

1. How broad are the chemical claims in Patent 7,910,767?
The claims cover a class of compounds with a core scaffold and specific substituents, providing broad coverage within defined structural parameters.

2. Can a competitor develop similar compounds outside the claimed substituents?
Yes, if the alternative compounds do not fall within the specific structures or use claims, they may avoid infringement.

3. Are the therapeutic claims enforceable across different diseases?
Claims include methods for treating multiple conditions, but enforcement may be limited to the diseases explicitly claimed during patent life.

4. What is the patent’s strength in the global market?
Strong in the US and Europe, with parallel applications in other jurisdictions, though local patent laws could influence enforceability.

5. What risks exist to the patent’s validity?
Prior art or disclosures identical or similar to the claimed compounds and uses could challenge validity. Patent office and court decisions will determine enforceability.


References

[1] U.S. Patent and Trademark Office. (2011). Patent 7,910,767. Retrieved from https://patents.google.com/patent/US7910767

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,910,767

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,910,767

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04100001Jan 5, 2004

International Family Members for US Patent 7,910,767

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047081 ⤷  Start Trial
Argentina 098931 ⤷  Start Trial
Australia 2004313688 ⤷  Start Trial
Brazil PI0418245 ⤷  Start Trial
Canada 2551409 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.